# EDGAR Filing Document

**Accession Number:** 0001698530
**File Stem:** 0001698530-25-000071
**Filing Date:** 2025-8
**Character Count:** 6085
**Document Hash:** cb05bc79e6bbdab799ea4b98baee3bf3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001698530-25-000071.hdr.sgml**: 20250804

**ACCESSION NUMBER**: 0001698530-25-000071

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250804

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20250804

**DATE AS OF CHANGE**: 20250804

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** EXICURE, INC.
- **CENTRAL INDEX KEY:** 0001698530
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 815333008
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39011
- **FILM NUMBER:** 251181137

**BUSINESS ADDRESS:**
- **STREET 1:** 2430 N. HALSTED ST.
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60614
- **BUSINESS PHONE:** 847-673-1707

**MAIL ADDRESS:**
- **STREET 1:** 2430 N. HALSTED ST.
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60614

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Max-1 Acquisition Corp
- **DATE OF NAME CHANGE:** 20170221

?xml version='1.0' encoding='ASCII'? xcur-20250804

    

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**____________________**

**FORM 8-K**

**____________________**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): August 4, 2025**

**____________________**

**EXICURE, INC.**

**(Exact name of Registrant as specified in its charter)**

**____________________**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39011** | **81-5333008** |
| **(State or other jurisdiction<br>of incorporation)** | **(Commission<br>File Number)** | **(IRS Employer<br>Identification No.)** |

---

**400 Seaport Court, Suite 102** 

**Redwood City, CA 94063**

**(Address of principal executive offices)**

**Registrant's telephone number, including area code: (847) 673-1700**

**____________________**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□&nbsp;&nbsp;&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□&nbsp;&nbsp;&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.0001 per share | XCUR | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company □

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

    

------

**Item 8.01 &nbsp;&nbsp;&nbsp;&nbsp;Other Events.**

On August 4, 2025, the Company issued a press release announcing the Company's receipt of the Letter from Nasdaq. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

**Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.**

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Description** |
| 99.1 | <u>[Press release dated August 4, 2025](aex991pressreleaseaug42025.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: August 4, 2025 | **EXICURE, INC.** | **EXICURE, INC.** |
|  | By: | /s/ Andy Yoo |
|  |  | Andy Yoo |
|  |  | Chief Executive Officer |

---

## Exhibit 99.1

---

| | |
|:---|:---|
| | **Exhibit 99.1** |
| ![exicureimage1a10a.gif](exicureimage1a10a.gif) | |

---

**Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements**

**Redwood City, CA** (BUSINESS WIRE) — **August 4, 2025** — Exicure, Inc. ("Exicure" or the "Company") (Nasdaq: XCUR) a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that, as of July 1, 2025, the Company regained compliance with the periodic filing requirement for The Nasdaq Stock Market under Listing Rule 5250(c)(1) (the "Rule") based on the filing of its periodic reports on Form 10-Q to the United States Securities and Exchange Commission for the fiscal quarter ended March 31, 2025. The Company has received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") confirming compliance with the Rule and stating that the matter has been resolved.

**About Exicure**

Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its recent restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value, both with respect to its historical biotechnology assets and more broadly. For further information, see www.exicuretx.com.

**Media Contact:**

Sarah Ellinwood, PhD

Kendall Investor Relations

sellinwood@kendallir.com

###

<br>